Inflammatory bowel disease

Updates on molecular targets for biologics

Konstantinos H. Katsanos, Konstantinos Papadakis

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalGut and Liver
Volume11
Issue number4
DOIs
StatePublished - Jul 1 2017

Fingerprint

Biological Products
Inflammatory Bowel Diseases
Therapeutics
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Interleukin-11
Cytokines
Janus Kinases
Interleukin-18
Interleukin-13
Interleukin-17
Toll-Like Receptors
Transforming Growth Factors
Regulatory T-Lymphocytes
Cell- and Tissue-Based Therapy
Integrins
Interleukin-10
Interleukin-6
Leukocytes
T-Lymphocytes

Keywords

  • Colitis
  • Crohn disease
  • Inflammatory bowel disease
  • Molecular targets
  • Therapy targets
  • Ulcerative

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Inflammatory bowel disease : Updates on molecular targets for biologics. / Katsanos, Konstantinos H.; Papadakis, Konstantinos.

In: Gut and Liver, Vol. 11, No. 4, 01.07.2017, p. 455-463.

Research output: Contribution to journalReview article

@article{a80c4ed67d7b42f5a103dddde58424c5,
title = "Inflammatory bowel disease: Updates on molecular targets for biologics",
abstract = "Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.",
keywords = "Colitis, Crohn disease, Inflammatory bowel disease, Molecular targets, Therapy targets, Ulcerative",
author = "Katsanos, {Konstantinos H.} and Konstantinos Papadakis",
year = "2017",
month = "7",
day = "1",
doi = "10.5009/gnl16308",
language = "English (US)",
volume = "11",
pages = "455--463",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "4",

}

TY - JOUR

T1 - Inflammatory bowel disease

T2 - Updates on molecular targets for biologics

AU - Katsanos, Konstantinos H.

AU - Papadakis, Konstantinos

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.

AB - Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.

KW - Colitis

KW - Crohn disease

KW - Inflammatory bowel disease

KW - Molecular targets

KW - Therapy targets

KW - Ulcerative

UR - http://www.scopus.com/inward/record.url?scp=85021836192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021836192&partnerID=8YFLogxK

U2 - 10.5009/gnl16308

DO - 10.5009/gnl16308

M3 - Review article

VL - 11

SP - 455

EP - 463

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 4

ER -